In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AngioScore Inc.

Division of Royal Philips NV

Latest From AngioScore Inc.

Medtech 2014: M&A, IPOs Bounce Back As Industry Glimpses Future Business Models

Healthy market growth, the biggest ever M&A deal, a record number of billion-dollar takeovers, and the IPO market in impressive bounce-back…2014 was a year of superlatives for the global medtech industry. But with more expected of manufacturers while health care spending remains in the doldrums and demand for care rises, the long-term medtech winners will be those who can forecast how and where to make an impact on both costs and patient outcomes.

Medical Device Deals

Medtech In 2014: M&A, IPOs Bounce Back As Industry Glimpses Future Business Models

Medtech manufacturers saw 2014 as the year of the medtech mega-merger and a rebound in IPOs. But the market is changing, and companies are increasingly cast as service providers who must deliver value.

Medical Device Deals

Device/Diagnostics Quarterly Deal Statistics, Q2 2014

Device funding increased 123% to $1.6 billion in Q2, and M&A activity was overshadowed by Medtronic’s massive $47 billion acquisition of Covidien. Diagnostics fundraising dropped slightly to $522 million, and there were multiple takeovers of life sciences companies.

Medical Device Deals

Deals In Depth: May 2014

As Valeant continues its pursuit of Allergan, the spec pharma divested its aesthetics products to Galderma for $1.4 billion; Merck and Boston Scientific also sold off major OTC and interventional businesses, respectively. Biopharma funding was down from the previous month to just over $1 billion, while device financing was slightly up to $390 million.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Royal Philips NV
  • Senior Management
  • Thomas R Trotter, Pres. & CEO
    James B Andrews, SVP, CFO
    Gary Gershony, MD, CMO
    Richard P Cassidy, SVP, Global Sales & Marketing
    Kent W Jones, SVP, Regulatory & Quality
    Samuel L Omaleki, SVP, Operations
    Jeff Bleam, VP, R&D
  • Contact Info
  • AngioScore Inc.
    Phone: (510) 933-7900
    5055 Brandin Ct.
    Fremont, CA 94538